Bluebird Bio, Inc. (BLUE)

NASDAQ: BLUE · IEX Real-Time Price · USD
8.73
0.21 (2.46%)
At close: Jan 14, 2022 4:00 PM
8.75
0.02 (0.23%)
After-hours:Jan 14, 2022 7:55 PM EST
Market Cap612.04M
Revenue (ttm)53.65M
Net Income (ttm)-864.20M
Shares Out70.11M
EPS (ttm)-12.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,251,309
Open8.57
Previous Close8.52
Day's Range8.18 - 8.78
52-Week Range8.12 - 33.55
Beta1.61
AnalystsHold
Price Target13.08 (+49.8%)
Earnings DateNov 3, 2021

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (C...

IndustryBiotechnology
IPO DateJun 19, 2013
Employees1,201
Stock ExchangeNASDAQ
Ticker SymbolBLUE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for Bluebird Bio stock is "Hold." The 12-month stock price forecast is 13.08, which is an increase of 49.83% from the latest price.

Price Target
$13.08
(49.83% upside)
Analyst Consensus: Hold

News

Why Bluebird Bio Stock Is Sinking This Week

The biotech's latest corporate update wasn't well received by investors this week.

2 days ago - The Motley Fool

Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference

Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference, including 2022 program milestones and financial outlook.

5 days ago - Benzinga

bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Health...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference including 2022 program milestone...

5 days ago - Business Wire

bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40th Annual J.P. Morgan Healthcare Conference, Wednes...

1 week ago - Business Wire

4 Biotechs That Were Winners at ASH

Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.

Other symbols:AGIOBMYFMTX
2 weeks ago - The Motley Fool

bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.

3 weeks ago - Zacks Investment Research

Why Bluebird Bio Stock Is Plunging Today

The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.

3 weeks ago - The Motley Fool

Why Are Bluebird Bio Shares Trading Lower Today?

The FDA has placed a partial clinical hold on Bluebird bio Inc's (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) gene therapy program for sickle cell disease (SCD) for patients under the age of 18....

3 weeks ago - Benzinga

UPDATE: Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program

Bluebird Bio Inc. BLUE, +13.34% said Monday the Food and Drug Administration has placed a partial clinical hold on patients below the age of 18 in its lovo-cel sickle cell gene therapy program. The temp...

3 weeks ago - Market Watch

Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program

Bluebird Bio Inc. BLUE, +13.34% said Monday the Food and Drug Administration has placed a partial clinical hold on patients below the age of 18 in its lovo-cel sickle cell gene therapy program. The temp...

3 weeks ago - Market Watch

bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell d...

3 weeks ago - Business Wire

Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold

The FDA has accepted for priority review Buebird bio Inc's (NASDAQ: BLUE) marketing application for elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) in patients less t...

3 weeks ago - Benzinga

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adr...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License App...

4 weeks ago - Business Wire

Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

1 month ago - Zacks Investment Research

Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program

Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD, bb1111) gene therapy for sickle cell dis...

1 month ago - Benzinga

New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Thera...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (NASDAQ: BLUE) today announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlo...

1 month ago - Business Wire

New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented new results for betibeglogene autotemcel (beti-cel), a deeply studied investigational gene therapy, that de...

1 month ago - Business Wire

2 Popular Healthcare Stocks I'd Avoid at All Costs

There's an entire galaxy full of better places to invest your money.

Other symbols:TEVA
1 month ago - The Motley Fool

bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review

bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.

1 month ago - Zacks Investment Research

Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA

The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has granted priority review for Beti-cel, gene therapy ...

1 month ago - Benzinga

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients wi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for b...

1 month ago - Business Wire

Why Bluebird Bio Stock Plunged Today

Two analysts downgraded the biotech stock.

2 months ago - The Motley Fool

bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates.

2 months ago - Zacks Investment Research

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021. “This quarter was about prep...

2 months ago - Business Wire